Erratum: Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA (Molecular and Cellular Biochemistry (2011) 350 (71-80) DOI: 10.1007/s11010-010-0683-3);Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA

Molecular and Cellular Biochemistry

Volumn 350, Issue 1-2, 2011, Pages 71-80

  Brodská, Barbora ^a   Otevřelová, Petra ^a   Holoubek, Aleš ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Apoptosis; CML; Decitabine; Peripheral blood lymphocytes; SAHA

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BH3 PROTEIN; CASPASE; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; VORINOSTAT;

ACETYLATION; APOPTOSIS; ARTICLE; CELL DEATH; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; PERIPHERAL LYMPHOCYTE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 79953691791     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-012-1259-1     Document Type: Erratum

References (60)

1. Jain N, Rossi A, Garcia-Manero G (2009) Epigenetic therapy of leukemia: an update. Int J Biochem Cell Biol 41:72-80
2. Daskalakis M, Blagitko-Dorfs N, Hackanson B (2010) Decitabine. Recent Results Cancer Res 184:131-157
3. Garcia-Manero G (2008) Demethylating agents in myeloid malignancies. Curr Opin Oncol 20:705-710
4. Gurion R, Vidal L, Gafter-Gvili A, Belnik Y, Yeshurun M, Raanani P, Shpilberg O (2010) 5-Azacitidine prolongs overall survival in patients with myelodysplastic syndrome - systematic review and meta-analysis. Haematologica 95(2):303-310
5. Issa JP, Kantarjian HM (2009) Targeting DNA methylation. Clin Cancer Res 15:3938-3946
6. Amatori S, Papalini F, Lazzarini R, Donati B, Bagaloni I, Rippo MR, Procopio A, Pelicci PG, Catalano A, Fanelli M (2009) Decitabine, differently from DNMT1 silencing, exerts its anti-proliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells. Lung Cancer 66:184-190
7. Jiemjit A, Fandy TE, Carraway H, Bailey KA, Baylin S, Herman JG, Gore SD (2008) p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage. Oncogene 27:3615-3623 (Pubitemid 351793797)
8. Scott SA, Dong WF, Ichinohasama R, Hirsch C, Sheridan D, Sanche SE, Geyer CR, Decoteau JF (2006) 5-Aza-2′-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation. Leuk Res 30:69-76 (Pubitemid 41654707)
9. Wang H, Zhao Y, Li L, McNutt MA, Wu L, Lu S, Yu Y, Zhou W, Feng J, Chai G, Yang Y, Zhu WG (2008) An ATM- and Rad3- related (ATR) signaling pathway and a phosphorylation-acetylation cascade are involved in activation of p53/p21Waf1/Cip1 in response to 5-aza-2′-deoxycytidine treatment. J Biol Chem 283:2564-2574
10. Zheng QH, Ma LW, Zhu WG, Zhang ZY, Tong TJ (2006) p21Waf1/Cip1 plays a critical role in modulating senescence through changes of DNA methylation. J Cell Biochem 98:1230-1248 (Pubitemid 44128362)
11. Furukawa Y, Sutheesophon K, Wada T, Nishimura M, Saito Y, Ishii H, Furukawa Y (2005) Methylation silencing of the Apaf-1 gene in acute leukemia. Mol Cancer Res 3:325-334 (Pubitemid 40905624)
12. Shang D, Liu Y, Matsui Y, Ito N, Nishiyama H, Kamoto T, Ogawa O (2008) Demethylating agent 5-aza-2′-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin. Urology 71:1220-1225 (Pubitemid 351763776)
13. Yagi S, Oda-Sato E, Uehara I, Asano Y, Nakajima W, Takeshita T, Tanaka N (2008) 5-Aza-2′-deoxycytidine restores proapoptotic function of p53 in cancer cells resistant to p53-induced apoptosis. Cancer Invest 26:680-688
14. Tamm I, Wagner M, Schmelz K (2005) Decitabine activates specific caspases downstream of p73 in myeloid leukemia. Ann Hematol 84(suppl 1):47-53
15. Lavelle D, DeSimone J, Hankewych M, Kousnetzova T, Chen YH (2003) Decitabine induces cell cycle arrest at the G1 phase via p21(WAF1) and the G2/M phase via the p38 MAP kinase pathway. Leuk Res 27:999-1007 (Pubitemid 36809073)
16. Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H (2008) Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer 112:2341-2351
17. Qin T, Jelinek J, Si J, Shu J, Issa JP (2009) Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. Blood 113:659-667
18. Batty N, Malouf GG, Issa JP (2009) Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 280:192-200
19. Lee EJ, Lee BB, Kim SJ, Park YD, Park J, Kim DH (2008) Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells. Int J Oncol 33:767-776
20. Li Q, Bartlett DL, Gorry MC, O'Malley ME, Guo ZS (2009) Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms. Mol Pharmacol 76(5):1072-1081
21. Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, Takai N, Komatsu N, Chumakov A, Imai Y, Koeffler HP (2007) Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 121:656-665 (Pubitemid 46986501)
22. Jiang X, Tsang YH, Yu Q (2007) c-Myc overexpression sensitizes Bim-mediated Bax activation for apoptosis induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through regulating Bcl-2/Bcl-xL expression. Int J Biochem Cell Biol 39:1016-1025 (Pubitemid 46584827)
23. Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rotzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O (2008) Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 80:133-142
24. Lobjois V, Frongia C, Jozan S, Truchet I, Valette A (2009) Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids. Eur J Cancer 45:2402-2411
25. Seo SK, Jin HO, Lee HC, Woo SH, Kim ES, Yoo DH, Lee SJ, An S, Rhee CH, Hong SI, Choe TB, Park IC (2008) Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells. Mol Pharmacol 73:1005-1012
26. Kuzelova K, Pluskalova M, Brodska B, Otevrelova P, Elknerova K, Grebenova D, Hrkal Z (2010) Suberoylanilide hydroxamic acid (SAHA) at subtoxic concentrations increases the adhesivity of human leukemic cells to fibronectin. J Cell Biochem 109:184-195
27. Wozniak MB, Villuendas R, Bischoff JR, Aparicio CB, Martinez Leal JF, de La Cueva P, Rodriguez ME, Herreros B, Martin-Perez D, Longo MI, Herrera M, Piris MA, Ortiz-Romero PL (2010) Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. Haematologica 95:613-621
28. Brodska B, Otevrelova P, Kalousek I (2009) Variations in c-Myc and p21WAF1 expression protect normal peripheral blood lymphocytes against BimEL-mediated cell death. Cell Biochem Funct 27:167-175
29. Bonazzi VF, Irwin D, Hayward NK (2009) Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma. Genes Chromosom Cancer 48:10-21
30. Carambula SF, Oliveira LJ, Hansen PJ (2009) Repression of induced apoptosis in the 2-cell bovine embryo involves DNA methylation and histone deacetylation. Biochem Biophys Res Commun 388:418-421
31. Chai G, Li L, Zhou W, Wu L, Zhao Y, Wang D, Lu S, Yu Y, Wang H, McNutt MA, Hu YG, Chen Y, Yang Y, Wu X, Otterson GA, Zhu WG (2008) HDAC inhibitors act with 5-aza-2′-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells. PLoS One 3:e2445
32. Ecke I, Petry F, Rosenberger A, Tauber S, Monkemeyer S, Hess I, Dullin C, Kimmina S, Pirngruber J, Johnsen SA, Uhmann A, Nitzki F, Wojnowski L, Schulz-Schaeffer W, Witt O, Hahn H (2009) Antitumor effects of a combined 5-aza-2′-deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Cancer Res 69:887-895
33. De Bruyne E, Bos TJ, Schuit F, Van Valckenborgh E, Menu E, Thorrez L, Atadja P, Jernberg-Wiklund H, Vanderkerken K (2010) IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood 115:2430-2440
34. Gore SD (2009) In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment? Leuk Res 33(Suppl 2):S2-S6
35. Cho HJ, Kim SY, Kim KH, Kang WK, Kim JI, Oh ST, Kim JS, An CH (2009) The combination effect of sodium butyrate and 5-Aza-2′-deoxycytidine on radiosensitivity in RKO colorectal cancer and MCF-7 breast cancer cell lines. World J Surg Oncol 7:49
36. Steele N, Finn P, Brown R, Plumb JA (2009) Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer 100:758-763
37. Kalousek I, Brodska B, Otevrelova P, Roselova P (2007) Actinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes. Anticancer Drugs 18:763-772 (Pubitemid 46975962)
38. Gillissen B, Essmann F, Hemmati PG, Richter A, Richter A, Oztop I, Chinnadurai G, Dorken B, Daniel PT (2007) Mcl-1 determines the Bax dependency of Nbk/Bik-induced apoptosis. J Cell Biol 179:701-715 (Pubitemid 350146256)
39. Gallenne T, Gautier F, Oliver L, Hervouet E, Noel B, Hickman JA, Geneste O, Cartron PF, Vallette FM, Manon S, Juin P (2009) Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members. J Cell Biol 185:279-290
40. Whitman SP, Hackanson B, Liyanarachchi S, Liu S, Rush LJ, Maharry K, Margeson D, Davuluri R, Wen J, Witte T, Yu L, Liu C, Bloomfield CD, Marcucci G, Plass C, Caligiuri MA (2008) DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood 112:2013-2016
41. Nishioka C, Ikezoe T, Yang J, Komatsu N, Koeffler HP, Yokoyama A (2009) Blockade of MEK signaling potentiates 5-Aza-2′-deoxycytidine-induced apoptosis and upregulation of p21(waf1) in acute myelogenous leukemia cells. Int J Cancer 125:1168-1176
42. Almond JB, Cohen GM (2002) The proteasome: a novel target for cancer chemotherapy. Leukemia 16:433-443 (Pubitemid 34449723)
43. Zhao Y, Lu S, Wu L, Chai G, Wang H, Chen Y, Sun J, Yu Y, Zhou W, Zheng Q, Wu M, Otterson GA, Zhu WG (2006) Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol 26:2782-2790
44. Yamaguchi H, Woods NT, Piluso LG, Lee HH, Chen J, Bhalla KN, Monteiro A, Liu X, Hung MC, Wang HG (2009) p53 acetylation is crucial for its transcription-independent proapoptotic functions. J Biol Chem 284:11171-11183
45. Tang YA, Wen WL, Chang JW, Wei TT, Tan YH, Salunke S, Chen CT, Chen CS, Wang YC (2010) A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer. PLoS One 5:e12417
46. Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E, Yao TP (2001) p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 20:1331-1340 (Pubitemid 32233973)
47. Carlisi D, Vassallo B, Lauricella M, Emanuele S, D'Anneo A, Di Leonardo E, Di Fazio P, Vento R, Tesoriere G (2008) Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects. Int J Oncol 32:177-184 (Pubitemid 351176076)
48. Kantarjian HM, Issa JP (2005) Decitabine dosing schedules. Semin Hematol 42:S17-S22 (Pubitemid 40961868)
49. Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, Okawa Y, Ikeda H, Vallet S, Pozzi S, Ishitsuka K, Ocio EM, Chauhan D, Anderson KC (2007) 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA doublestrand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther 6:1718-1727 (Pubitemid 46954048)
50. Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD (2008) DNA methylation inhibitor 5-Aza-2′-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol 28:752-771
51. Garrison SP, Jeffers JR, Yang C, Nilsson JA, Hall MA, Rehg JE, Yue W, Yu J, Zhang L, Onciu M, Sample JT, Cleveland JL, Zambetti GP (2008) Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol Cell Biol 28:5391-5402
52. Hoglund A, Nilsson LM, Forshell LP, Maclean KH, Nilsson JA (2009) Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine. Blood 113:4281-4288
53. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW (1993) MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A 90:3516-3520 (Pubitemid 23111397)
54. Michels J, Johnson PW, Packham G (2005) Mcl-1. Int J Biochem Cell Biol 37:267-271 (Pubitemid 39330187)
55. Akgul C (2009) Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci 66:1326-1336
56. Mandelin AM 2nd, Pope RM (2007) Myeloid cell leukemia-1 as a therapeutic target. Expert Opin Ther Targets 11:363-373
57. Warr MR, Shore GC (2008) Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med 8:138-147 (Pubitemid 351516833)
58. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, Huang DC (2005) Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17:393-403 (Pubitemid 40193310)
59. Willis SN, Adams JM (2005) Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 17:617-625 (Pubitemid 41540411)
60. Yang Y, Zhao S, Song J (2004) Caspase-dependent apoptosis and -independent poly(ADP-ribose) polymerase cleavage induced by transforming growth factor beta1. Int J Biochem Cell Biol 36(2):223-234 (Pubitemid 37487758)